|
US2003022253A1
|
|
Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
|
|
AU2002255705A1
|
|
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
|
AU3660802A
|
|
High throughput assay to detect inhibitors of the map kinase pathway
|
|
AU7136601A
|
|
Neuroactive peptides for treatment of hypoxia and related conditions
|
|
AU6846701A
|
|
Identification of genes and compounds for treatment of cancer
|
|
AU1922301A
|
|
Differential gene expression in cancer
|
|
US6194158B1
|
|
Diagnostic assay for cancer
|
|
US6274314B1
|
|
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
|
EP1077217A2
|
|
Neuroactive peptides and their use
|
